Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Trellus Health PLC ( (GB:TRLS) ) has provided an update.
Trellus Health has renewed its licensing agreement with Pfizer, under which the pharma giant will continue using Trellus’s patient-support educational content within its inflammatory bowel disease digital application. The deal extends an existing collaboration that highlights the relevance of Trellus’s resilience-focused methodology across the pharmaceutical value chain, alongside agreements with partners such as Gastro Health and Johnson & Johnson.
The company said its average monthly cash burn has been reduced to about $300,000 as of March 2026, and that the Pfizer renewal, together with a loan from scientific co-founder Laurie Keefer, should extend its cash runway into May 2026. The board is backing Trellus Health’s commercial strategy and is in talks over additional funding options to further strengthen liquidity, underscoring the importance of converting its growing pipeline of partnerships into sustainable revenue.
Spark’s Take on TRLS Stock
According to Spark, TipRanks’ AI Analyst, TRLS is a Neutral.
The score is held down primarily by weak financial performance—large ongoing losses, negative free cash flow, and declining equity—despite the benefit of having no debt. Technicals are the main positive, with strong momentum above major moving averages, but valuation remains constrained by loss-making results and no indicated dividend yield.
To see Spark’s full report on TRLS stock, click here.
More about Trellus Health PLC
Trellus Health plc is a healthcare company that delivers Trellus Elevate®, a digital, resilience-based platform combining data analytics, personalised self‑management programmes and expert support for people with complex chronic conditions. The group initially targets high-cost gastrointestinal diseases such as inflammatory bowel disease, and also markets Trellus TrialSet™ to pharmaceutical partners to support clinical trials and long-term patient engagement.
Average Trading Volume: 9,912,027
Technical Sentiment Signal: Sell
Current Market Cap: £547.3K
Find detailed analytics on TRLS stock on TipRanks’ Stock Analysis page.